Dechra Pharmaceuticals PLC Completion of Acquisition (7888E)

TIDMDPH

RNS Number : 7888E

Dechra Pharmaceuticals PLC

13 February 2018

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, HONG KONG, SINGAPORE OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES WITHIN THIS ANNOUNCEMENT.

13 February 2018

Dechra Pharmaceuticals PLC ("Dechra")

Completion of Acquisition

Dechra is pleased to announce that the Acquisition of AST Farma B.V. ("AST Farma") and Le Vet Beheer B.V. ("Le Vet") has now completed. Admission of the 3,670,625 Consideration Shares is expected on the 14 February 2018.

 
 For further information contact: 
---------------------------------------  -------------------- 
 
   Dechra Pharmaceuticals PLC               Tel: [phone] 
                                            814 730 
 Ian Page, Chief Executive Officer 
 Richard Cotton, Chief Financial 
  Officer 
 e-mail: [e-mail] 
 
 Investec Bank plc (Sole Sponsor,         Tel: +44 (0) 20 
  Bookrunner and Broker)                   7597 5970 
 Chris Treneman / Daniel Adams 
  / Jonathan Wynn / Neil Coleman 
 
 TooleyStreet Communications Limited      Office: +44 (0) 
                                           121 309 0099 
 Fiona Tooley, Director                   Mobile: +44 (0) 
                                           7785 703 523 
 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of its products are focused on key therapeutic categories where it has leading market positions, and many of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

IMPORTANT NOTICES

This announcement is for information purposes only and is not intended to and does not constitute, or form part of, any offer or invitation to purchase, subscribe for or otherwise acquire or dispose of, or any solicitation to purchase or subscribe for or otherwise acquire or dispose of, any securities in any jurisdiction. Persons needing advice should consult an independent financial adviser. The information contained in this announcement is not for release, publication or distribution to persons in any jurisdiction where to do so might constitute a violation of local securities laws or regulations.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. The information in this announcement is subject to change without notice.

Investec Bank plc ("Investec") is authorised by the Prudential Regulatory Authority and regulated in the United Kingdom by the Prudential Regulation Authority and the Financial Conduct Authority and is acting exclusively for Dechra and no one else in connection with the Acquisition, the content of this announcement and other matters described in this announcement. Investec will not regard any other person as their client in relation to the Acquisition, the content of this announcement and other matters described in this announcement and will not be responsible to anyone other than Dechra for providing the protections afforded to their respective clients or for providing advice to any other person in relation to the Acquisition, the content of this announcement or any other matters referred to in this announcement.

This announcement has been issued by and is the sole responsibility of Dechra. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Investec or by any of its affiliates or agents as to, or in relation to, the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on behalf of it, Dechra or any other person in connection with Dechra, the Acquisition or for any other written or oral information made available to or publicly available to any interested party or its advisers, and nothing in this announcement should be read as a promise or representation in this respect, whether or not to the past or the future. Each of Investec and its affiliates and agents disclaims to the fullest extent permitted by law all and any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, which it might otherwise have in respect of this announcement or any such statement.

Neither the content of Dechra's website (or any other website) nor the content of any website accessible from hyperlinks on Dechra's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQUOVVRWBAUAAR

(END) Dow Jones Newswires

February 13, 2018 10:59 ET (15:59 GMT)